Drug intelligence / Profile preview

ruyizhenbao pill

Development stage
Phase 2
Lead developer
Arula Tibetan Medicine Group
Modality
Small Molecules
Administration
Oral
01

Overview

Ruyizhenbao Pill is a classic oral Tibetan herbal medicine composed of approximately 29–30 medicinal ingredients including pearl, cassia seed, bezoar, saffron (*Carthamus tinctorius*), amomum (*Amomum kravanh*), licorice (*Glycyrrhiza uralensis*), *Aquilaria sinensis*, *Eugenia caryophyllata*, *Myristica fragrans*, *Phyllanthus emblica*, *Santalum album*, and Lignum dalbergiae odoriferae[1][2][5]. It is traditionally used for the treatment of neurological and vascular conditions such as stroke (including limb numbness and paralysis), lumbar disc herniation (pain and dysfunction), acute spinal cord injury (SCI), neuropathic pain, gout, Baimai disease (“white channels” disease in Tibetan medicine), old fever/plague syndromes[1][3][4][5][6]. Mechanistically, its effects are attributed to multi-target actions including inhibition of the CXCL10-CXCR3 pathway in neuropathic pain models; modulation of immune response by reducing Treg cell proportion via the TUG1/miR-214/HSP27 signaling axis; regulation of estrogen receptor expression; inhibition of arrhythmias via SCN5A modulation; anti-inflammatory effects through PIK3CG/NOS2/NOS3/JUN/CASP3/F7/AKT1 pathways[1][4][5][6]. It has been approved for use in China since April 2020 for indications such as gout and is under clinical investigation for lumbar disc herniation. The main active components identified include agarotetrol (from Aquilariae Lignum Resinatum), piperine (from Piper longum L.), isoliquiritigenin (from Dalbergia odorifera T. Chen), ferulic acid (from licorice cream)[2].

Brand names
Ruyizhenbao PillRuyi Zhenbao tabletZhenbao Pill
Other names
Ruyi Zhenbao tabletZhenbao PillRYZB
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CCR3 (C-C chemokine receptor type 3)CASP3 (Caspase-3)F7 (Coagulation Factor VII)ER (Estrogen receptor)JUN (Transcription factor Jun)NOS2 (Nitric Oxide Synthase 2)NOS3 (eNOS)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on ruyizhenbao pill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ruyizhenbao pill.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call